Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
CARBIOS and Landbell Group join forces to increase circularity of PET waste at…
CARBIOS and Landbell Group join forces to increase circularity of PET waste at first biorecycling plantCARBIOS and Landbell Group sign agreement to develop and implement solutions for the sorting, preparation and enzymatic recycling of post-consumer PET wasteCARBIOS and Landbell Group combine expertise and innovation to significantly increase PET recycling from packaging and textile waste This partnership contributes 15kt/year of PET flakes to CARBIOS' sourcing roadmap for its...
Nasdaq GlobeNewswire
29/02/2024
DOVE, TOGETHER WITH ITS COMMUNITY, UNITE VOICES TO PROTECT GIRLS' SELF-ESTEEM…
To view the Multimedia New Release, Please click: https://www.multivu.com/players/uk/9254251-dove-protect-girls-self-esteem-anti-ageing-pressures/ To view the Multimedia New Release, Please click: https://www.multivu.com/players/uk/9254251-dove-protect-girls-self-esteem-anti-ageing-pressures/ The trend toward adult targeted anti-ageing skincare breeds premature appearance anxiety in young girls, which can negatively impact their self-esteem – now and in the future.Nearly 1 in 2 young...
PR Newswire
29/02/2024
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial…
"2023 was a year of continued strong execution that delivered top- and bottom-line growth and over $3.8 billion in total revenue. Sleep1 revenue exceeded $1.9 billion, Oncology revenue surpassed $1 billion and Epidiolex remains on track to deliver on its blockbuster potential, demonstrating our progress towards Vision 2025 targets. We also meaningfully advanced our late-stage pipeline and are pleased to note enrollment of the Phase 3 Zepzelca® trial in first-line small cell lung cancer has…
PR Newswire
28/02/2024
Hospital Beds Market Witnessing Unprecedented Growth Amidst Healthcare…
The Global Hospital Beds Market Report Scope The Global Hospital Beds Market Report Scope Europeis the largest revenue contributor for the global hospital beds market (2023). Full-electric hospital beds enable patients with reduced mobility to move freely. In recent years, there has been a rising prevalence of patients suffering from chronic and other acute disease conditions such as spinal injuries, paralysis, and others. This patient population demands full-electric...
PR Newswire
28/02/2024
Full-year 2023 results
Ludwig de Mot appointed Chief Executive OfficerStrategic Review outcome: launch of the FOCUS-27 project to improve competitiveness and unlock sustainable & profitable growthFull-Year 2023 results: resilience in a challenging business environment1,013.2 million in Net Sales, up 3.8% 1€93.1 million Core EBITDA,with a9.2% Core EBITDA margin, down from 12.3% in 2022 due to unfavorable fixed cost absorption and input cost inflation€226.4 million impairment on Tangible...
Nasdaq GlobeNewswire
28/02/2024
The Enteral Feeding Devices Market to Hit $4.85 Billion Revenue Opportunities by…
The Global Enteral Feeding Devices Market Report Scope The Global Enteral Feeding Devices Market Report Scope North Americais the largest revenue contributor for the global Enteral Feeding Devices market (2023). The global enteral feeding devices market is fragmented, with many global, regional, and local players offering diverse enteral feeding pumps, feeding tubes, and related accessories/consumables. The highly competitive market is dominated by Avanos Medical, Applied Medical...
PR Newswire
28/02/2024
RAMSAY SANTE : Half-year results at end of December 2023
PRESS RELEASE Paris, 28 February 2024 Half-year results at the end of December 2023As a mission-driven company, Ramsay Santé continues its support for the care of all patients and all pathologies, both in France and in the Nordic countries, in complementarity with public hospitals.Ramsay Santé has maintained the implementation of its key initiatives as part of its “Yes We Care 2025” strategy to offer integrated care to patients, by increasing its portfolio of...
Nasdaq GlobeNewswire
28/02/2024
Infection Control Market Worth $69.2 billion | MarketsandMarkets™
Technological advancements like automation, artificial intelligence in disinfection robots, and nanotechnology-based antimicrobial surfaces offer promising solutions. Sustainability is gaining traction, with eco-friendly disinfectants and reusable personal protective equipment (PPE) gaining favor. Furthermore, growing awareness of occupational hazards in healthcare settings fuels demand for safer equipment and training. This dynamic market is poised for continued growth, driven by the relentless…
PR Newswire
28/02/2024
Coloplast A/S - Trading in Coloplast shares by board members, executives or…
Please see enclosed pdf. Attachment 28022024_trading_in_shares_GL
Nasdaq GlobeNewswire
28/02/2024
Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its…
"We are excited to announce that after successfully advancing in our SKY-0515 Phase 1 single ascending dose study, the safety review committee has recommended initiation of the multiple asending dose portion of our Phase 1," said Douglas Faller, Chief Medical Officer of Skyhawk Therapeutics. "Following this, we expect to begin enrolling Huntington's patients, who presently have few therapeutic options and none that reverse or slow disease progression. SKY-0515 has demonstrated…
PR Newswire
28/02/2024
Study Shows Synergistic Power of Lumenato® on Skin Structure and Collagen…
To assess the effectiveness of Lumenato in this study, specifically when combined with ceramides, the authors mimicked environmental stressors on skin cells by activating them with Tumor Necrosis Factor alpha (TNF-a) to trigger an immune response. The results found two-fold benefits from using Lumenato combined with ceramides. After testing both Lumenato and ceramides alone, the benefits of combining showed significant improvement (nearly 4x) on preventing collagen loss in the cells…
PR Newswire
28/02/2024
RRD International is now RRD Biopharma Development
The rebrand includes a new updated website showcasing its innovative Product Development Team (PDT) Model. The PDT model enables biopharma companies with limited infrastructure to navigate the challenges of drug development efficiently and effectively resulting in more predictable product development outcomes. The rebrand includes a new updated website showcasing its innovative Product Development Team (PDT) Model. The PDT model enables biopharma companies with limited infrastructure to...
PR Newswire
28/02/2024
Aurora Partners with Script Assist to Provide Better Access to UK Medical…
EDMONTON, AB, Feb. 28, 2024 /PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, today announced the partnership of Aurora Medicine UK Ltd with Script Assist, a cutting-edge medical cannabis prescription platform in the UK. EDMONTON, AB,Feb. 28, 2024/PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, today announced the partnership of Aurora Medicine...
PR Newswire
28/02/2024
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington's disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory interactions and clarity on potential strategies for clinical development expected in 2024 ~ ~ Announced FDA clearance of two Investigational New Drug (IND) applications; Initiation of Phase I/II clinical trials in mesial temporal lobe epilepsy (mTLE) and Fabry disease, in addition to SOD1-ALS, are...
Nasdaq GlobeNewswire
28/02/2024
Lutris Pharma Receives FDA Orphan Drug Designation for LUT014 for the Treatment…
"As a result of the dermal toxicity caused by EGFR inhibitors, many of these patients do not receive the optimal treatment against their cancer, either due to dose reduction or even discontinuation, caused by the rash," added Antoni Ribas, M.D., Ph.D., Chairman and Founder of Lutris Pharma. "Importantly, results from our phase 1 trial of LUT014 in patients with metastatic colorectal cancer who had developed grade 2 rash demonstrated the safety of the approach as well as provided…
PR Newswire
28/02/2024
First product based on LTS Sorrel™ wearable drug delivery platform launched in…
Bas van Buijtenen, CEO of LTS, commented: "This launch completes the market entry of LTS into Biologics, bringing the ease of administration that LTS's solutions are known for to new class of therapies. Our capacity is ready to scale up, providing access to this advantageous solution to all patients swiftly." Bas van Buijtenen, CEO of LTS, commented: "This launch completes the market entry of LTS into Biologics, bringing the ease of administration that LTS's solutions are known…
PR Newswire
28/02/2024
Tilray Provides International Cannabis Update on Milestone German Cannabis…
Germany's De-Scheduling of Cannabis Opens Path to New Opportunities for Tilray in Potential $3bn Medical MarketEuropean Union Medical Cannabis Market Now Projected to Become $45bn NEW YORK and NEUMÜNSTER, Germany, Feb.28, 2024(GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today provides an update on Germany's milestone cannabis legalization and what it means for the future...
Nasdaq GlobeNewswire
28/02/2024
New technology aiming to improve patients' outcomes in breast cancer
Breast cancer is the most common female cancer in the WHO Europe region, accounting for 1 in 4 new cancer diagnoses with an estimated incidence of more than half a million in 2020, making it the leading cause of cancer death in women. [i] Breast cancer is the most common female cancer in the WHO Europe region, accounting for 1 in 4 new cancer diagnoses with an estimated incidence of more than half a million in 2020, making it the leading cause of cancer death in women. [i] Through...
PR Newswire
28/02/2024
Pet Toys Market to Reach $18.4 Billion, Globally, by 2032 at 8.0% CAGR: Allied…
Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A07037 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A07037 Prime determinants of growth The growing trend of pet humanization is contributing to the growth of the pet toy market. In addition, increase in desire to spend on individual pets has boosted the demand for pet food, veterinary care, insurance, and other supplies, including...
PR Newswire
28/02/2024
Philips extends leadership in virtually helium-free MRI with more than 1,000…
At #ECR2024, company also debuting Europe's first mobile virtually helium-free MRI systemAmsterdam, the Netherlands and Vienna, Austria – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a significant milestone as it expands access to virtually helium-free [1] MRI to more patients in more places, with more than 1,000 systems now installed worldwide. As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 ...
Nasdaq GlobeNewswire
28/02/2024
Essity's Annual Report for 2023
Read the complete CEO message and about Essity's strategic priorities, earnings and leading sustainability work in the Annual Report for 2023, which is attached to this press release and can be downloaded at essity.com. Read the complete CEO message and about Essity's strategic priorities, earnings and leading sustainability work in the Annual Report for 2023, which is attached to this press release and can be downloaded atessity.com. The Annual Report also contains a cohesive...
PR Newswire
28/02/2024
SciBase Partners with Skinobs to Offer Nevisense on Global Cosmetic Testing…
"SciBase is already involved in discussions with several large cosmetic companies who wish to use Nevisense in their research and development. In May this year, SciBase will present and exhibit at its first cosmetic research-focused international conference, the Cosmetotest cosmetics testing symposium in Lyon, France," said Pia Renaudin, CEO at SciBase. "We are excited to be partnering with Skinobs to bring our innovative skin barrier function assessment technique to researchers…
PR Newswire
28/02/2024
Natural Personal Care Ingredients Market worth $7.9 billion by 2028 - Exclusive…
Browse in-depth TOC on "Natural Cosmetics Ingredients Market" Browse in-depth TOC on "Natural Cosmetics Ingredients Market" Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=181363323 "Surfactants are projected to register the highest CAGR, in terms of value, of the global natural personal care ingredients market during the forecast period." Surfactants are expected to grow rapidly in the natural personal care ingredients market due to…
PR Newswire
28/02/2024
Casino Group: Release of the FY 2023 presentation results
RELEASE OF THE FULL YEAR 2023 EARNINGS PRESENTATION The Group has released its full-year 2023 earnings presentation on its website. It is available following this link: https://www.groupe-casino.fr/wp-content/uploads/2024/02/2024-02-28-Presentation-FY-2023-Results.pdfANALYST AND INVESTOR CONTACTSChristopher Welton– +33 (0)1 53 65 64 17 cwelton.exterieur@groupe-casino.fror+33 (0)1 53 65 24 17 IR_Casino@groupe-casino.fr PRESS CONTACTSCasino Group –...
Nasdaq GlobeNewswire
28/02/2024
Altri Comunicati